HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes
NA Doria-Rose, MK Louder, Z Yang, S O'Dell… - Journal of …, 2012 - Am Soc Microbiol
NA Doria-Rose, MK Louder, Z Yang, S O'Dell, M Nason, SD Schmidt, K McKee, MS Seaman…
Journal of virology, 2012•Am Soc MicrobiolABSTRACT HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine
development and are being considered for passive prevention of infection. We analyzed the
interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently
neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-
competition and displayed additive, though not synergistic, neutralization activity. Predicted
neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.
development and are being considered for passive prevention of infection. We analyzed the
interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently
neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-
competition and displayed additive, though not synergistic, neutralization activity. Predicted
neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.
Abstract
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are being considered for passive prevention of infection. We analyzed the interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-competition and displayed additive, though not synergistic, neutralization activity. Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.
American Society for Microbiology